|
1F81
SOLUTION STRUCTURE OF THE TAZ2 DOMAIN OF THE TRANSCRIPTIONAL ADAPTOR PROTEIN CBP
Deposited 2000-06-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1764–1850(87 aa)
Fragment:TAZ2 DOMAIN (1764-1850)
|
Not recorded
|
ZN ZINC ION × 3
|
SOLUTION NMR
NMR measurement conditions
pH 5.9;298 K;Ionic strength (raw mmCIF value) 25 mM;Pressure 1
NMR sample composition
1.5 mM Taz2 | 25 mM deuterated acetate 0.1 mM ZnCl2 0.1 mM DTT pH 5.9
|
Resolution not provided
|
|
1JJS
NMR Structure of IBiD, A Domain of CBP/p300
Deposited 2001-07-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
2067–2112(46 aa)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.5;298 K
|
Resolution not provided
|
|
1KBH
Mutual Synergistic Folding in the Interaction Between Nuclear Receptor Coactivators CBP and ACTR
Deposited 2001-11-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
2059–2117(59 aa)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.6;31 K;Ionic strength (raw mmCIF value) 60 mM;Pressure ambient
NMR measurement conditions
pH 6.6;31 K;Ionic strength (raw mmCIF value) 60 mM;Pressure ambient
NMR measurement conditions
pH 6.6;31 K;Ionic strength (raw mmCIF value) 60 mM;Pressure ambient
NMR measurement conditions
pH 6.6;31 K;Ionic strength (raw mmCIF value) 60 mM;Pressure ambient
NMR measurement conditions
pH 6.6;31 K;Ionic strength (raw mmCIF value) 60 mM;Pressure ambient
NMR measurement conditions
pH 6.6;31 K;Ionic strength (raw mmCIF value) 60 mM;Pressure ambient
NMR sample composition
3mM U-15N,13C-CBP:2059-2117
6mM 14N,12C-ACTR:1018-1088 | 10 mM Tris,
50 mM NaCl
95%H2O,5%D2O
NMR sample composition
3mM U-15N,12C-CBP:2059-2117
6mM 14N,12C-ACTR:1018-1088 | 10 mM Tris,
50 mM NaCl
95%H2O,5%D2O
NMR sample composition
3mM U-15N,13C-CBP:2059-2117
6mM 14N,12C-ACTR:1018-1088 | 10 mM Tris,
50 mM NaCl
100%D2O
NMR sample composition
2mM U-15N,13C-ACTR:1018-1088
4mM 14N,12C-CBP:2059-2117 | 10 mM Tris,
50 mM NaCl
95%H2O,5%D2O
NMR sample composition
2mM U-15N,12C-ACTR:1018-1088
4mM 14N,12C-CBP:2059-2117 | 10 mM Tris,
50 mM NaCl
95%H2O,5%D2O
NMR sample composition
2mM U-15N,13C-ACTR:1018-1088
4mM 14N,12C-CBP:2059-2117 | 10 mM Tris,
50 mM NaCl
100%D2O
|
Resolution not provided
|
|
1KDX
KIX DOMAIN OF MOUSE CBP (CREB BINDING PROTEIN) IN COMPLEX WITH PHOSPHORYLATED KINASE INDUCIBLE DOMAIN (PKID) OF RAT CREB (CYCLIC AMP RESPONSE ELEMENT BINDING PROTEIN), NMR 17 STRUCTURES
Deposited 1997-09-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
586–666(81 aa)
Fragment:KIX, RESIDUES 586-666
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 5.5;315 K;Ionic strength (raw mmCIF value) 0.07;Pressure 1
NMR sample composition
H2O OR D2O
|
Resolution not provided
|
|
1L8C
STRUCTURAL BASIS FOR HIF-1ALPHA/CBP RECOGNITION IN THE CELLULAR HYPOXIC RESPONSE
Deposited 2002-03-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
345–439(95 aa)
Fragment:TAZ1 (Transcription activation zinc finger) domain, Residues 345-439
|
Not recorded
|
ZN ZINC ION × 3
|
SOLUTION NMR
NMR measurement conditions
pH 6.1;298 K;Ionic strength (raw mmCIF value) 2.0 Millimolar;Pressure Ambient
NMR sample composition
1MM 13C, 15N-TAZ1, 2MM HIF-1a
NMR sample composition
1MM 13C, 15N-HIF-1a, 2MM TAZ1
NMR sample composition
10MM D-TRIS, 10MM D-DTT, 0.02% NAN3, 0.5MM ZnSO4
|
Resolution not provided
|
|
1SB0
Solution structure of the KIX domain of CBP bound to the transactivation domain of c-Myb
Deposited 2004-02-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
580–666(87 aa)
Fragment:KIX domain
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 5.5;27 K;Ionic strength (raw mmCIF value) 50 mM;Pressure ambient
NMR sample composition
20 mM Tris d11 acetate d4; 50 mM NaCl; 2 mM NaN3; pH 5.5 | 90% H20; 10% D2O
|
Resolution not provided
|
|
1TOT
ZZ Domain of CBP- a Novel Fold for a Protein Interaction Module
Deposited 2004-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1700–1751(52 aa)
Fragment:ZZ domain of murine CBP (residues 1700-1751)
|
Not recorded
|
ZN ZINC ION × 2
|
SOLUTION NMR
NMR measurement conditions
pH 6.8;298 K;Ionic strength (raw mmCIF value) 10 mM;Pressure ambient
NMR sample composition
2.3 mM solutions in degassed 10 mM Tris-d11 pH 6.8, 200 M ZnCl2, 10 mM DTT-d10, 0.05% w/v sodium azide, 94 % H2O, 6 % D2O | 94 % H2O, 6 % D2O
|
Resolution not provided
|
|
1U2N
Structure CBP TAZ1 Domain
Deposited 2004-07-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
340–439(100 aa)
Fragment:CBP TAZ1 Domain
|
Not recorded
|
ZN ZINC ION × 3
|
SOLUTION NMR
NMR measurement conditions
pH 6.9;298 K;Ionic strength (raw mmCIF value) 50mM;Pressure ambient
NMR sample composition
1mM N15 TAZ1; 10mM Tris-d11 pH 6.9; 50mM NaCl; 2mM DTT | 90% H2O, 10% 2H2O
NMR sample composition
1mM C13,N15 TAZ1; 10mM Tris-d11 pH 6.9; 50mM NaCl; 2mM DTT | 100% 2H2O
NMR sample composition
1mM C13,N15 TAZ1; 10mM Tris-d11 pH 6.9; 50mM NaCl; 2mM DTT | 90% H2O, 10% 2H2O
|
Resolution not provided
|
|
2AGH
Structural basis for cooperative transcription factor binding to the CBP coactivator
Deposited 2005-07-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain B
586–672(87 aa)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 5.5;298 K;Pressure 1
NMR sample composition
0.5-0.8 mM 15N,13C-labeled protein (e.g. CBP) + 3 fold excess of unlabeled binding partners (MYB + MLL), 20 mM Tris-d3-acetate, 50 mM NaCl, 0.2% sodium azide, 10% D2O | 20 mM Tris-d3-acetate, 50 mM NaCl, 0.2% sodium azide, 10% D2O
NMR sample composition
13C,15N-MYB + UNLABELED CBP & MYB, 20 mM Tris-d3-acetate, 50 mM NaCl, 0.2% sodium azide, 10% D2O | 20 mM Tris-d3-acetate, 50 mM NaCl, 0.2% sodium azide, 10% D2O
NMR sample composition
13C,15N-MLL + UNLABELED CBP & MLL, 20 mM Tris-d3-acetate, 50 mM NaCl, 0.2% sodium azide, 10% D2O | 20 mM Tris-d3-acetate, 50 mM NaCl, 0.2% sodium azide, 10% D2O
|
Resolution not provided
|
|
2C52
Structural diversity in CBP p160 complexes
Deposited 2005-10-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
2059–2117(59 aa)
Fragment:SID, RESIDUES 2059-2117
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 100
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 100
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 100
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 100
NMR sample composition
90% WATER/10% D2O
NMR sample composition
90% WATER/10% D2O
NMR sample composition
100% D2O
NMR sample composition
100% D2O
|
Resolution not provided
|
|
2KA6
NMR structure of the CBP-TAZ2/STAT1-TAD complex
Deposited 2008-10-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
1764–1855(92 aa)
Fragment:UNP residues 1764 to 1855
|
Not recorded
|
ZN ZINC ION × 3
|
SOLUTION NMR
NMR measurement conditions
pH 6.8;290 K;Ionic strength (raw mmCIF value) 0.05;Pressure ambient
NMR sample composition
1 mM [U-100% 15N] TAZ2, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
2KKJ
Solution structure of the Nuclear coactivator binding domain of CBP
Deposited 2009-06-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
2059–2117(59 aa)
Fragment:Nuclear coactivator binding domain, UNP residues 2059-2441
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.5;31 K;Ionic strength (raw mmCIF value) 0.1;Pressure ambient
NMR sample composition
10 % D2O-1, 20 mM sodium chloride-2, 20 mM sodium phosphate-3, 2 mM [U-100% 13C; U-100% 15N] protein-4, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
2L14
Structure of CBP nuclear coactivator binding domain in complex with p53 TAD
Deposited 2010-07-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
2059–2117(59 aa)
Fragment:CBP nuclear coactivator binding domain
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.5;298 K;Ionic strength (raw mmCIF value) 0.05;Pressure ambient
NMR sample composition
0.5 mM [U-99% 15N] CBP nuclear coactivator binding domain, 0.5 mM [U-99% 15N] p53 TAD, 0.5 mM [U-99% 13C; U-99% 15N] CBP nuclear coactivator binding domain, 0.5 mM [U-99% 13C; U-99% 15N] p53 TAD, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
2LQH
NMR structure of FOXO3a transactivation domains (CR2C-CR3) in complex with CBP KIX domain (2b3l conformation)
Deposited 2012-03-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
586–672(87 aa)
Fragment:KIX domain
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6;303 K;Ionic strength (raw mmCIF value) 0.05;Pressure ambient
NMR sample composition
0.6 mM [U-100% 13C; U-100% 15N] KIX, 0.6 mM CR2C-CR3, 20 mM MES, 50 mM sodium chloride, 1 mM DTT, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
0.6 mM [U-100% 13C; U-100% 15N] KIX, 0.6 mM CR2C-CR3, 20 mM MES, 50 mM sodium chloride, 1 mM DTT, 100% D2O | 100% D2O
NMR sample composition
0.6 mM [U-100% 13C; U-100% 15N] CR2C-CR3, 0.6 mM KIX, 20 mM MES, 50 mM sodium chloride, 1 mM DTT, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
0.6 mM [U-100% 13C; U-100% 15N] CR2C-CR3, 0.6 mM KIX, 20 mM MES, 50 mM sodium chloride, 1 mM DTT, 100% D2O | 100% D2O
|
Resolution not provided
|
|
2LQI
NMR structure of FOXO3a transactivation domains (CR2C-CR3) in complex with CBP KIX domain (2l3b conformation)
Deposited 2012-03-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
586–672(87 aa)
Fragment:KIX DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6;303 K;Ionic strength (raw mmCIF value) 0.05;Pressure ambient
NMR sample composition
0.6 mM [U-100% 13C; U-100% 15N] KIX, 0.6 mM CR2C-CR3, 20 mM MES, 50 mM sodium chloride, 1 mM DTT, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
0.6 mM [U-100% 13C; U-100% 15N] KIX, 0.6 mM CR2C-CR3, 20 mM MES, 50 mM sodium chloride, 1 mM DTT, 100% D2O | 100% D2O
NMR sample composition
0.6 mM [U-100% 13C; U-100% 15N] CR2C-CR3, 0.6 mM KIX, 20 mM MES, 50 mM sodium chloride, 1 mM DTT, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
0.6 mM [U-100% 13C; U-100% 15N] CR2C-CR3, 0.6 mM KIX, 20 mM MES, 50 mM sodium chloride, 1 mM DTT, 100% D2O | 100% D2O
|
Resolution not provided
|
|
2LWW
NMR structure of RelA-TAD/CBP-TAZ1 complex
Deposited 2012-08-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
340–439(100 aa)
Fragment:TAZ-type 1 zinc finger residues 340-439
|
Not recorded
|
ZN ZINC ION × 3
|
SOLUTION NMR
NMR measurement conditions
pH 6.5;298 K;Ionic strength (raw mmCIF value) 40;Pressure ambient
NMR sample composition
0.8-1.1 mM [U-13C; U-15N] TAZ1, 1.2-1.5 mM RelA-TA2, 2 mM DTT, 20 mM TRIS, 40 mM sodium chloride, 5 % [U-2H] D2O, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition
0.8-1.1 mM [U-13C] TAZ1, 1.2-1.5 mM RelA-TA2, 2 mM [U-2H] DTT, 20 mM [U-2H] TRIS, 40 mM sodium chloride, 99.8 % [U-2H] D2O, 100% D2O | 100% D2O
NMR sample composition
0.7-0.9 mM [U-13C] RelA-TA2, 1.5-1.8 mM TAZ1, 2 mM [U-2H] DTT, 20 mM [U-2H] TRIS, 40 mM sodium chloride, 99.8 % [U-2H] D2O, 100% D2O | 100% D2O
NMR sample composition
0.7-0.9 mM [U-13C; U-15N] RelA-TA2, 1.5-1.8 mM TAZ1, 2 mM DTT, 20 mM TRIS, 40 mM sodium chloride, 5 % [U-2H] D2O, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition
0.8-1.1 mM [U-15N] TAZ1, 1.2-1.5 mM RelA-TA2, 2 mM DTT, 20 mM TRIS, 40 mM sodium chloride, 5 % [U-2H] D2O, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition
0.7-0.9 mM [U-15N] RelA-TA2, 1.5-1.8 mM TAZ1, 2 mM DTT, 20 mM TRIS, 40 mM sodium chloride, 5 % [U-2H] D2O, 95% H2O/5% D2O | 95% H2O/5% D2O
|
Resolution not provided
|
|
4I9O
Crystal Structure of GACKIX L664C Tethered to 1-10
Deposited 2012-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
586–672(87 aa)
Fragment:UNP residues 562-672, GACKIX domain
|
Mutation:L664C
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
KI1 1-{4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl}-3-sulfanylpropan-1-one × 1
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;1.8 M (NH4)2SO4, 0.1 M Tris-HCl, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å
R-free 0.233
|
|
4I9O
Crystal Structure of GACKIX L664C Tethered to 1-10
Deposited 2012-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
586–672(87 aa)
Fragment:UNP residues 562-672, GACKIX domain
|
Mutation:L664C
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
KI1 1-{4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl}-3-sulfanylpropan-1-one × 2
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;1.8 M (NH4)2SO4, 0.1 M Tris-HCl, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å
R-free 0.233
|
|
5HOU
Solution Structure of p53TAD-TAZ1
Deposited 2016-01-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
340–439(100 aa)
Fragment:p53TAD, TAZ1 domain of CBP
|
Not recorded
|
ZN ZINC ION × 3
|
SOLUTION NMR
NMR measurement conditions
pH 6.8;308 K;Ionic strength (raw mmCIF value) 50;Pressure 1
NMR measurement conditions
pH 6.4;308 K;Ionic strength (raw mmCIF value) 50;Pressure 1
NMR sample composition
1.0 mM [U-15N] p53TAD - [NA] TAZ1 p53TAD-TAZ1 fusion protein, 20 mM TRIS, 50 mM sodium chloride, 2 mM DTT, 5 % [U-2H] D2O, 95% H2O, 5% D2O | 95% H2O/5% D2O
NMR sample composition
1.0 mM [U-15N][U-13C] p53TAD - [NA] TAZ1 p53TAD-TAZ1 fusion protein, 20 mM [U-2H] TRIS, 50 mM sodium chloride, 2 mM [U-2H] DTT, 99 % [U-2H] D2O, 99% D2O, 1% H2O | 99% D2O, 1% H2O
NMR sample composition
1.0 mM [NA] p53TAD - [U-15N] TAZ1 p53TAD-TAZ1 fusion protein, 20 mM TRIS, 50 mM sodium chloride, 2 mM DTT, 5 % [U-2H] D2O, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition
1.0 mM [NA] p53TAD - [U-15N][U-13C] TAZ1 p53TAD-TAZ1 fusion protein, 20 mM [U-2H] TRIS, 50 mM sodium chloride, 2 mM [U-2H] DTT, 99 % [U-2H] D2O, 99% D2O, 1% H2O | 99% D2O, 1% H2O
NMR sample composition
1.0 mM [U-15N][U-13C] p53TAD - [NA] TAZ1 p53TAD-TAZ1 fusion protein, 20 mM TRIS, 50 mM sodium chloride, 2 mM DTT, 5 % [U-2H] D2O, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition
1 mM [NA] p53TAD - [U-15N][U-13C] TAZ1 p53TAD-TAZ1 fusion protein, 20 mM TRIS, 50 mM sodium chloride, 2 mM DTT, 5 % [U-2H] D2O, 95% H2O/5% D2O | 95% H2O/5% D2O
|
Resolution not provided
|
|
5HP0
Solution Structure of TAZ2-p53AD2
Deposited 2016-01-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1764–1855(92 aa)
Fragment:p53AD2, TAZ2 domain of CBP
|
Not recorded
|
ZN ZINC ION × 3
|
SOLUTION NMR
NMR measurement conditions
pH 6.8;305 K;Ionic strength (raw mmCIF value) 50;Pressure 1
NMR measurement conditions
pH 6.4;305 K;Ionic strength (raw mmCIF value) 50;Pressure 1
NMR sample composition
1 mM [U-13C; U-15N] TAZ2-p53AD2, 20 mM TRIS, 50 mM sodium chloride, 2 mM DTT, 10 % [U-2H] D2O, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM [U-13C; U-15N] TAZ2-p53AD2, 20 mM [U-2H] TRIS, 50 mM sodium chloride, 2 mM [U-2H] DTT, 99 % [U-2H] D2O, 99% D2O, 1% H2O | 99% D2O, 1% H2O
NMR sample composition
1 mM [U-13C; U-15N] TAZ2-p53AD2, 20 mM TRIS, 50 mM sodium chloride, 2 mM DTT, 5 % [U-2H] D2O, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM [U-13C] TAZ2, 1 mM p53AD2(38-61), 20 mM [U-2H] TRIS, 50 mM sodium chloride, 2 mM [U-2H] DTT, 5 % [U-2H] D2O, 99% D2O, 1% H2O | 99% D2O, 1% H2O
NMR sample composition
1 mM [U-13C] p53AD2, 1 mM TAZ2, 20 mM [U-2H] TRIS, 50 mM sodium chloride, 2 mM [U-2H] DTT, 99 % [U-2H] D2O, 99% D2O, 1% H2O | 99% D2O, 1% H2O
|
Resolution not provided
|
|
5HPD
Solution Structure of TAZ2-p53TAD
Deposited 2016-01-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1764–1855(92 aa)
Fragment:p53TAD, TAZ2 domain of CBP
|
Not recorded
|
ZN ZINC ION × 3
|
SOLUTION NMR
NMR measurement conditions
pH 6.8;305 K;Ionic strength (raw mmCIF value) 50;Pressure 1
NMR measurement conditions
pH 6.4;305 K;Ionic strength (raw mmCIF value) 50;Pressure 1
NMR sample composition
1.75 mM [U-13C; U-15N] TAZ2-p53TAD, 20 mM TRIS, 50 mM sodium chloride, 1 mM DTT, 10 % [U-2H] D2O, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1.75 mM [U-13C; U-15N] TAZ2-p53TAD, 20 mM [U-2H] TRIS, 50 mM sodium chloride, 1 mM [U-2H] DTT, 99 % [U-2H] D2O, 99% D2O, 1% H2O | 99% D2O, 1% H2O
NMR sample composition
1 mM [U-13C] TAZ2, 1 mM p53(13-37, 1 mM p53(38-61), 50 mM sodium chloride, 2 mM [U-2H] DTT, 99 % [U-2H] D2O, 20 mM [U-2H] TRIS, 99% D2O, 1% H2O | 99% D2O, 1% H2O
NMR sample composition
1 mM TAZ2, 1 mM [U-13C] p53(13-37), 1 mM [U-13C] p53(38-61), 20 mM [U-2H] TRIS, 50 mM sodium chloride, 2 mM [U-2H] DTT, 99 % [U-2H] D2O, 99% D2O, 1% H2O | 99% D2O, 1% H2O
NMR sample composition
1 mM TAZ2, 1 mM [U-15N] p53(13-61), 20 mM TRIS, 50 mM sodium chloride, 2 mM DTT, 10 % [U-2H] D2O, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM [U-15N] TAZ2, 1 mM p53(13-61), 20 mM TRIS, 50 mM sodium chloride, 2 mM DTT, 10 % [U-2H] D2O, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM TAZ2, 1 mM [U-13C] p53(13-61), 20 mM [U-2H] TRIS, 50 mM sodium chloride, 2 mM [U-2H] DTT, 99 % [U-2H] D2O, 99% D2O, 1% H2O | 99% D2O, 1% H2O
NMR sample composition
1 mM [U-13C] TAZ2, 1 mM p53(13-61), 20 mM [U-2H] TRIS, 50 mM sodium chloride, 2 mM [U-2H] DTT, 99 % [U-2H] D2O, 99% D2O, 1% H2O | 99% D2O, 1% H2O
|
Resolution not provided
|
|
5W0I
CREBBP Bromodomain in complex with Cpd8 (1-(3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(tetrahydrofuran-3-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one)
Deposited 2017-05-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1083–1198(116 aa)
Fragment:Bromodomain, UNP residues 1083-1198
|
Not recorded
|
9UA 1-{3-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-1-[(3S)-oxolan-3-yl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one × 1
DMS DIMETHYL SULFOXIDE × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 6.5;277 K;0.2 M Li2SO4, 0.1M Bis-Tris pH 6.5, 23% PEG33500
|
Resolution 1.43 Å
R-free 0.192
|
|
6DNQ
HBZ77 in complex with KIX and c-Myb
Deposited 2018-06-07
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 5
PDB declaration: pentameric
|
Chain B
586–672(87 aa)
Fragment:residues 586-672
Chain D
586–672(87 aa)
Fragment:residues 586-672
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;PEG 3350, calcium chloride
|
Resolution 2.35 Å
R-free 0.229
|
|
7LVS
The CBP TAZ1 Domain in Complex with a CITED2-HIF-1-Alpha Fusion Peptide
Deposited 2021-02-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
340–439(100 aa)
|
Not recorded
|
ZN ZINC ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.1 M HEPES pH 6.87, 28% PEG 4000
|
Resolution 2.02 Å
R-free 0.241
|